Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)

Technology appraisal guidance
Published: 27 October 2010
nice.org.uk/guidance/ta206
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)

<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advice</td>
<td>3</td>
</tr>
<tr>
<td>Background</td>
<td>4</td>
</tr>
<tr>
<td>Information</td>
<td>5</td>
</tr>
<tr>
<td>Related NICE guidance</td>
<td>5</td>
</tr>
</tbody>
</table>
Advice

NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen because no evidence submission was received from the manufacturer or sponsor of the technology.
Background

The manufacturer of bendamustine (Napp Pharmaceuticals) was invited to submit evidence for this single technology appraisal (STA) in May 2010.

In June 2010, the manufacturer informed NICE that it would not be making an evidence submission because it was unable to identify relevant sources of clinical evidence suitable for a NICE appraisal in people with rituximab-refractory disease. The manufacturer indicated that further research was ongoing but data would not be available in a time frame that would allow NICE to produce timely guidance.

NICE has therefore terminated this single technology appraisal.
Information

NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen. If, after doing this, organisations still wish to consider the use of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen, they should follow the advice set out in ‘Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance’ which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.

NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

Related NICE guidance

For information about NICE guidance that has been issued or is in development, see the website.

Published

- **Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37).** NICE technology appraisal guidance 137 (2008).


Accreditation

www.nice.org.uk/accreditation